Solvay Finance announces the success of its tender offer on perp N.C. June 2021 hybrid bond, repurchasing 91.58% of the nominal amount
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA OR TO ANY U.S. PERSON OR IN OR INTO ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT.
Brussels, 2 September 2020 --- Following the closing of the cash tender offer on 1 September 2020, Solvay publishes the final results of the repurchase operation related to the €500 million 5.118% deeply subordinated perpetual hybrid bonds (ISIN: XS1323897485).
Solvay Finance intends to repurchase 91.58% of the outstanding aggregate principal amount for a total amount of €457,877,000.
Following the completion and settlement of the tender offer contemplated on 4 September 2020, more than 90% of the initial aggregate principal amount of the bonds will have been purchased by Solvay Finance. Pursuant to the terms and conditions of the bonds, Solvay Finance will have the option, at any time, to redeem all of the remaining outstanding bonds that were not validly tendered for purchase pursuant to the tender offer at their principal amount together with any accrued and unpaid interest (including any deferred interest) up to the redemption date. Solvay Finance intends to exercise this option as soon as practicable following the settlement of the tender offer
* * * * *
This announcement does not constitute an offer to sell, or a solicitation of an offer to purchase or subscribe for, securities (the “Offer”) in any jurisdiction in which, or to any person to or from whom, it is unlawful. The distribution of this announcement in certain jurisdictions may be restricted by law.
The Offer has not been made, directly or indirectly in or into, or by use of the mail of, or by any means or instrumentality of interstate or foreign commerce of, or of any facilities of a national securities exchange of, the United States. This includes, but is not limited to, facsimile transmission, electronic mail, telex, telephone, the internet and other forms of electronic communication. Accordingly, copies of the Tender Offer Memorandum, this announcement and any other documents or materials relating to the Offer were not, directly or indirectly mailed or otherwise transmitted, distributed or forwarded (including, without limitation, by custodians, nominees or trustees) in or into the United States or to any person located or resident in the United States and the Bonds were not tendered in the Offer by any such use, means, instrumentality or facility or from within the United States or by any person located or resident in the United States. Any purported tender of Bonds in the Offer resulting directly or indirectly from a violation of these restrictions were invalid and any purported tender of Bonds made by any person located in the United States or any agent, fiduciary or other intermediary acting on a non-discretionary basis for a principal giving instructions from within the United States were invalid and were not accepted.
Each holder of Bonds participating in the Offer has represented that it was not located in the United States and was not participating in the Offer from the United States, or it was acting on a non-discretionary basis for a principal located outside the United States that was not giving an order to participate in the Offer from the United States. For the purposes of this and the above paragraph, “United States” means the United States of America, its territories and possessions (including Puerto Rico, the U.S. Virgin Islands, Guam, American Samoa, Wake Island and the Northern Mariana Islands), any state of the United States of America and the District of Columbia.
None of the Offer, the Tender Offer Memorandum, this announcement or any other document or materials relating to the Offer were submitted to the clearance procedures of the Commissione Nazionale per le Società e la Borsa (CONSOB) pursuant to Italian laws and regulations. The Offer has been carried out in Italy as an exempted offer pursuant to article 101-bis, paragraph 3-bis of the Legislative Decree No. 58 of 24 February 1998, as amended (the “Financial Services Act”) and article 35-bis, paragraph 4 of CONSOB Regulation No. 11971 of 14 May 1999, as amended. Accordingly, Holders or beneficial owners of the Bonds that were located in Italy could tender Bonds for purchase pursuant to the Offer through authorised persons (such as investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance with the Financial Services Act, CONSOB Regulation No. 20307 of 15 February 2018, as amended from time to time, and Legislative Decree No. 385 of 1 September 1993, as amended) and in compliance with applicable laws and regulations or with requirements imposed by CONSOB, the Bank of Italy or any other Italian authority. Each intermediary must have complied with the applicable laws and regulations concerning information duties vis-à-vis its clients in connection with the Bonds and/or the Offer.
The communication of the Tender Offer Memorandum, this announcement and any other documents or materials relating to the Offer has not been made and such documents and/or materials were not approved by an authorised person for the purposes of section 21 of the Financial Services and Markets Act 2000. Accordingly, such documents and/or materials were not distributed to, and must not have been passed on to, the general public in the United Kingdom. The communication of such documents and/or materials as a financial promotion was only being made to those persons in the United Kingdom falling within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Financial Promotion Order”)) or persons who are existing members or creditors of the Offeror or other persons falling within Article 43(2) of the Financial Promotion Order or any other persons to whom it may otherwise lawfully be communicated in accordance with the Financial Promotion Order.
The Tender Offer Memorandum, this announcement and any other offering material relating to the Offer may have been distributed in France only to qualified investors (investisseurs qualifiés) as defined in Article 2(e) of Regulation (EU) 2017/1129 (the “Prospectus Regulation”). Neither the Tender Offer Memorandum, this announcement, nor any other such offering material have been submitted for clearance to, nor approved by the Autorité des Marchés Financiers.
Neither the Tender Offer Memorandum, this announcement nor any other documents or materials relating to the Offer have been notified to, and neither the Tender Offer Memorandum, this announcement nor any other documents or materials relating to the Offer have been approved by, the Belgian Financial Services and Markets Authority (Autoriteit voor Financiële Diensten en Markten/Autorité des Services et Marchés Financiers). The Offer may therefore not have been made in Belgium by way of a public takeover bid (openbaar overnamebod/offre publique d’acquisition) as defined in Article 3 of the Belgian law of 1 April 2007 on public takeover bids, as amended (the “Belgian Takeover Law”), save in those circumstances where a private placement exemption was available. The Offer has been conducted exclusively under applicable private placement exemptions. The Offer may therefore not have been advertised and the Offer was not extended, and neither the Tender Offer Memorandum, this announcement nor any other documents or materials relating to the Offer have been distributed or made available, directly or indirectly, to any person in Belgium other than (i) to qualified investors within the meaning of Article 2 (e) of the Prospectus Regulation and (ii) in any circumstances set out in Article 6, §4 of the Belgian Takeover Law. The Tender Offer Memorandum and this announcement were issued for the personal use of the above-mentioned qualified investors only and exclusively for the purpose of the Offer. Accordingly, the information contained in the Tender Offer Memorandum and this announcement may not have been used for any other purpose nor may it have been disclosed to any other person in Belgium.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program23.9.2020 07:15:00 CEST | Press release
Novartis Gene Therapies to initiate new pivotal confirmatory study to evaluate use of AVXS-101 intrathecal (IT) formulation in older patients with SMA to further support registration Basel, September23, 2020– Novartis Gene Therapies recently received feedback from the US Food and Drug Administration (FDA) following their review of data from the STRONG study of the intrathecal (IT) formulation of AVXS-101 in older patients with spinal muscular atrophy (SMA). The FDA has acknowledged the potential of AVXS-101 IT in this patient population and recommends a pivotal confirmatory study to supplement the existing STRONG data and further support the regulatory submission for AVXS-101 IT. This guidance provides clarity on the path to registration for AVXS-101 IT. Trial design and other details are being evaluated and a comprehensive update on the overall Novartis SMA clinical development program will be provided at a future time following further discussions with health authorities. This reques
AND (Ticker: AND.AS) intends to rebrand the company22.9.2020 18:05:00 CEST | Press release
Supporting the turnaround and the new strategic direction of the company Capelle aan den IJssel, the Netherlands, 22 September 2020 - AND is happy to announce that it intends to change the company name and refresh its branding in Q4 2020. This change is designed to highlight the company’s new strategic direction as well as support and strengthen the transformation into a subscription based provider of premium location aware content and services. As announced on August 12th, the turnaround strategy has already delivered 22% revenue growth in the first half of 2020. AND believes the new company name and branding will help to drive continued revenue growth and put location-intelligence squarely at the center of the company’s profile. Further announcements will follow in Q4 2020. Ends About AND AND is an innovative location-aware content and service provider. Our focus is to create and deliver market leading, relevant, innovative and tailored content which fosters a safer and more sustaina
Wolters Kluwer Completes Divestment of ComplyTrack22.9.2020 17:30:00 CEST | Press release
Wolters Kluwer Completes Divestment of ComplyTrack September 22, 2020 - Wolters Kluwer announces today that it has completed the divestment of ComplyTrack to symplr, as originally announced on September 8, 2020. About Wolters Kluwer Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the healthcare; tax and accounting; governance, risk and compliance; and legal and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services. Wolters Kluwer reported 2019 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolt
Joint Stock Company “Olainfarm” Extraordinary Shareholders Meeting on September 22, 2020 at 15.00 has not been held due to lack of quorum22.9.2020 14:20:00 CEST | Press release
Joint Stock Company “Olainfarm” Extraordinary Shareholders Meeting on September 22, 2020 at 15.00 has not been held due to lack of quorum Joint Stock Company “Olainfarm” Management Board informs that for the Extraordinary Shareholders Meeting on September 22, 2020 at 15.00 pm shareholders who in total represented 3 877 425 voting shares or 27.53% of voting capital were registered, therefore shareholders' meeting did not take place due to lack of quorum. Olaine, September 22, 2020 Additional information: Jānis Dubrovskis Investor Relations Advisor of JSC Olainfarm Ph.: +371 29178878 email@example.com
RESOLUTIONS of the Annual General Meeting of Shareholders of JSC „Olainfarm” to be held on September 22, 202022.9.2020 13:05:00 CEST | Press release
RESOLUTIONS of the Annual General Meeting of Shareholders of JSC „Olainfarm” to be held on September 22, 2020 Report of the Board on results of operations in 2019. Resolution: To take notice of the Report of the Board of the JSC “Olainfarm” on results of operations in 2019. Voting results: decision is taken with the required majority of votes. Report of the Council on results of operations in 2019. Resolution: To take notice of the Report of the Council of the JSC “Olainfarm” on results of operations in 2019. Voting results: decision is taken with the required majority of votes. Approval of the JSC “Olainfarm” Consolidated Annual Report for 2019. Resolution: To approve the Consolidated and Parent Company’s Annual Report of JSC „Olainfarm” for 2019 with profit in amount of EUR 22 239 000,00. Voting results: decision is taken with the required majority of votes. Distribution of profit of 2019. Resolution: 4.1. To pay dividends to the shareholders of the Joint Stock Company" Olainfarm " i
ProMIS Neurosciences to develop multivalent vaccine for Alzheimer’s disease22.9.2020 12:30:10 CEST | Press release
Potential vaccine to incorporate ProMIS proprietary peptide antigens; early in vivo preclinical data demonstrate neuronal protection and improvement in cognitive deficits TORONTO and CAMBRIDGE, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today initiation of a program to construct and test a multivalent peptide vaccine for Alzheimer’s disease (AD). The critical first steps in vaccine development will be carried out by VIDO-InterVac, a global leader in vaccine research and development. Recent progress in the development of blood-based biomarkers for neurodegeneration is enabling increased screening to diagnose and identify individuals at risk of developing AD. A vaccine capable of inducing an effective antibody response against amyloid-beta toxic oligom